首页> 外文期刊>Scandinavian journal of rheumatology >Hypertrophic pachymeningitis associated with antineutrophil cytoplasmic antibody-associated vasculitis: a case series of 15 patients
【24h】

Hypertrophic pachymeningitis associated with antineutrophil cytoplasmic antibody-associated vasculitis: a case series of 15 patients

机译:肥厚性嗜血育炎与抗替托利罗氏菌细胞质抗体相关的血管炎:一个案例系列15名患者

获取原文
获取原文并翻译 | 示例
       

摘要

Objective: We aimed to describe the clinical characteristics and treatment course of hypertrophic pachymeningitis (HPM) in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Methods: We retrospectively analysed 15 patients (11 men and four women). HPM was diagnosed based on thickening and enhancing of the brain and/or spinal dura mater on gadolinium-enhanced magnetic resonance imaging (MRI) T1 sequence. Results: The median age at HPM onset was 60 years. Headache and cranial nerve impairment were observed in 14 and 10 patients, respectively. Otitis media and/or mastoiditis were found as complications of AAV in 11 patients. Fourteen patients were classified as having granulomatosis with polyangiitis (GPA). Single-positive myeloperoxidase-ANCA, single-positive proteinase 3-ANCA, and double-positive ANCA were identified in seven patients, five patients, and one patient, respectively. With MRI, thickening of the dura mater in the cranial fossa and tentorium cerebelli was found in 10 and eight patients, respectively. For remission induction, all patients were treated with corticosteroids, and immunosuppressants were added in 10 patients. Dura mater thickening partially improved in all patients, and cranial neuropathy completely remitted in eight patients. In a median follow-up of 43 months, four patients had HPM relapse and underwent reinduction therapy. All six patients treated with cyclophosphamide at initial therapy did not relapse. Conclusions: HPM was mostly associated with patients with GPA with otitis media and/or mastoiditis having either type of ANCA serology. Treatment with corticosteroids with or without immunosuppressants was effective. However, HPM relapse occasionally occurred, especially when cyclophosphamide was not used in initial treatment.
机译:目的:我们旨在描述抗嗜脱机细胞质抗体(ANCA) - 分配血管炎(AAV)患者患者肥厚性嗜肥症(HPM)的临床特征和治疗过程。方法:我们回顾性分析了15名患者(11名男子和四名妇女)。基于增厚和增强脑和/或脊柱硬脑膜碱基增强型磁共振成像(MRI)T1序列的增厚和增强,诊断为HPM。结果:HPM发作的中位年龄为60年。在14名和10名患者中观察到头痛和颅神经损伤。在11名患者中发现了中耳炎和/或乳囊炎作为AAV的并发症。十四名患者被归类为具有多苯炎(GPA)的肉芽肿病。分别在7名患者,五名患者和一名患者中鉴定单阳性髓氧化酶-ANCA,单阳性蛋白酶3-ANCA和双阳性ANCA。随着MRI,分别在10名和8名患者中发现了颅骨中的硬脑膜和呼啸症中的硬化。对于缓解诱导,所有患者均用皮质类固醇治疗,并在10名患者中加入免疫抑制剂。所有患者的硬脑膜增厚部分改善,八名患者的颅神经病变完全汇总。在43个月的中位随访中,四名患者有HPM复发和接受再生治疗。所有六名患者在初始治疗时用环磷酰胺治疗并未复发。结论:HPM大多与GPA患者与具有中耳炎和/或患有任何类型的ANCA血清学的乳突性有关。用免疫抑制剂的皮质类固醇治疗有效。然而,偶尔发生HPM复发,特别是当在初始治疗中不使用环磷酰胺时。

著录项

  • 来源
  • 作者单位

    Gunma Univ Grad Sch Med Dept Nephrol &

    Rheumatol 3-39-22 Showa Maebashi Gumma 3718511 Japan;

    Sanshikai Toho Hosp Dept Nephrol Gunma Japan;

    Gunma Univ Grad Sch Med Dept Nephrol &

    Rheumatol 3-39-22 Showa Maebashi Gumma 3718511 Japan;

    Gunma Univ Grad Sch Med Dept Nephrol &

    Rheumatol 3-39-22 Showa Maebashi Gumma 3718511 Japan;

    Gunma Univ Grad Sch Med Dept Nephrol &

    Rheumatol 3-39-22 Showa Maebashi Gumma 3718511 Japan;

    Gunma Univ Grad Sch Med Dept Nephrol &

    Rheumatol 3-39-22 Showa Maebashi Gumma 3718511 Japan;

    Japan Red Cross Maebashi Hosp Dept Rheumatol &

    Nephrol Gunma Japan;

    Gunma Univ Grad Sch Med Dept Nephrol &

    Rheumatol 3-39-22 Showa Maebashi Gumma 3718511 Japan;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 免疫性疾病;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号